SOUTH SAN FRANCISCO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) will release its fourth quarter and full year 2007 financial results on Thursday, February 14, 2008 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. ET/ 2:00 p.m. PT, in which Exelixis management will discuss the results and provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An audio replay of the webcast will be available until 11:59 p.m. ET/ 8:59 p.m. PT on March 15, 2008. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888, and the passcode is 86315644.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

SOURCE Exelixis, Inc.
CONTACT: Investors, Charles Butler, Senior Director, Corporate
Communications, +1-650-837-7277, cbutler@exelixis.com, or Media, Soleil
Maxwell Harrison, Senior Manager, Corporate Communications,
+1-650-837-7012, sharrison@exelixis.com, both of Exelixis, Inc.
Web site: http://www.exelixis.com